FEATURES OF THE COURSE AND DEVELOPMENT OF TYPE II DIABETES IN THE TREATMENT OF LATE-STAGE PROSTATE CANCER

Aim. To evaluate the effect of treatment of late-stage prostate cancer (prostate cancer) on the development and course of diabetes type II. Materials and Methods. The study included 232 patientswith prostate cancer (T4 - T3; Nx- N0- N1; Mx - M1; G1 - G3). In 87 (37.5%) patients, prostate cancer was accompanied by type II diabetes (insulin). It should be noted that in 19 (8.18%) patients with prostate cancer, with comorbidity of diabetes type II, body weight ranged from 48 kg to 79 kg (Group 1); in 68 (29.31%) patients, body weight ranged from 80 to 123 kg (-Group 2). In 145 patients with prostate cancer, signs of diabetes were observed upon primary treatment. In 122 (55,58%) patients with prostate cancer, body weight ranged from 48 to 79 kg (Group 3); in 23 patients (9,91%) - body weight ranged from 80 to 123 kg (Group 4). Criteria for evaluation of treatment: 1. Development of diabetes during treatment with androgen blockade maximum (MAB); 2. Type II diabetes progression during treatment with MAB. Evaluation of the results of research was carried out in 6 months, 1, 3 and 5 years after the application of MAB. Results and Discussion. During the study period, the development of type II diabetes during treatment with MAB in patients with advanced stages of prostate cancer was observed in patients of Groups 3 and 4. Accordingly, within 6 months from the date of the MAB, diabetes II was not detected in any case. After 1 year from the start of treatment one (0.81%) case of diabetes type II was observed in a patient of Group 3 and three cases (13.04%) in patients of Group 4. In the third year, type II diabetes was diagnosed in 3 (2.45%) patients of Group 3 and in one (4.34%) patient of Group 4. After 5 years of followup diabetes type II was found in 4 patients (3.27%)of Group 3 and in 4 (13.04%) patients of Group 4. The total number of patients of Groups 3 and 4 where the occurrence of type II diabetes was observed during treatment with MAB was 8 (6.56%) and 7 (30.43%), respectively. During the study period progression of diabetes type II in the background of MAB in patients with advanced stages of prostate cancer was observed in patients of Groups 1 and 2. Accordingly, within 6 months from the date of the MAB, progression of type II diabetes was not observed in any case. After 1 year of treatment of early progression of diabetes type II was recorded in only four 4 (5.88%) patients II group. In the third year, type II diabetes progressed in 1 (5.26%) patient of Group 1 and in 11 (16.18%) patients in Group 2. After 5 years of followup progression of diabetes type II was flagged in 2 patients (10.52%) of Group 1 and in 17 (25%) patients of Group 2. The total number of patients of Groups 1 and 2 with progression of diabetes type II in the background of the MAB was 3 (15.79%) and 32 (47.05%) cases, respectively. Conclusions. Application of MAB during the period of 6 months in the treatment of late-stage prostate cancer does not affect the development and progression of type II diabetes. The risk of developing type II diabetes in patients with advanced stages of prostate cancer weighing more than 80 kg during treatment with MAB for five years at 23.87% is higher compared with those patients with body weight under 80 kg. The established risk of progression of diabetes type II in patients with advanced stages of prostate cancer weighing 48-79 kg is not significant due to the small sample size.